Pine Labs Raises $75-100 Million in Fresh Funding at $2 Billion Valuation (Economic Times) Pine Labs has raised $75-$100 million led by US-based billionaire...
Keep Reading →
December 21 - Hedge Funds, Insider Trading - Comments
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors...
Keep Reading →
December 12 - Hedge Funds, News - Comments
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However...
Keep Reading →
July 4 - Hedge Funds, News - Comments
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook...
Keep Reading →
December 19 - Hedge Funds, News - Comments
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and...
Keep Reading →
October 30 - Hedge Funds, News - Comments
Is Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into...
Keep Reading →
June 26 - Hedge Funds, News - Comments
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by...
Keep Reading →
May 5 - Hedge Funds, News - Comments
Bill Ackman Makes More Layoffs at His Pershing Square Hedge Fund (CNBC) Billionaire hedge fund manager William Ackman, whose investment assets have shrunk...
Keep Reading →
June 27 - Hedge Funds, Insider Trading - Comments
‘Capitalism May Need Modernizing,’ Says Billionaire Hedge Fund Manager Paul Tudor Jones (CNBC) The 50-year-old definition of capitalism in...
Keep Reading →
June 12 - Hedge Funds, Insider Trading - Comments
Two companies have logged strong starts to the week in the biotech space so far, and both are moving on FDA driven catalysts. Here’s a look at these...
Keep Reading →
March 1 - News, Stock Analysis - Comments
Right then, it’s time to take a look at who moved during the start of this week, and what’s driving the action in the biotech sector. In a continuation...
Keep Reading →
December 6 - Market Movers, News, Stock Analysis - Comments
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the...
Keep Reading →
December 2 - Hedge Funds, News - Comments
When things go well in biotech, it can be a great ride. When things repeatedly go well, however, it can be easy to forget how quickly, and how frequently...
Keep Reading →
September 16 - News, Stock Analysis - Comments
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) gained considerably at the end of last week on the back of a data release from its ongoing type 1 diabetes...
Keep Reading →
September 13 - News, Stock Analysis - Comments
It is already common knowledge that individual investors do not usually have the necessary resources and ability to properly research an investment opportunity...
Keep Reading →
November 23 - Hedge Funds, News - Comments
Shares of Heron Therapeutics Inc (NASDAQ:HRTX) are up by more than 20% in early trading, following positive Phase 2 reports on HTX-011, an anesthetic...
Keep Reading →
September 23 - Hedge Funds, News - Comments
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) are flying high today, gaining nearly 60% on Monday, as the company announced positive results for...
Keep Reading →
August 3 - Hedge Funds, News - Comments
Is Nektar Therapeutics (NASDAQ:NKTR) a good investment? Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment...
Keep Reading →
September 17 - News - Comments
To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age. Although there are In excess of 8,000 hedge funds...
Keep Reading →
September 11 - News - Comments
Should PDL BioPharma Inc. (NASDAQ:PDLI) investors track the following data? In the eyes of many market players, hedge funds are seen as overrated, old...
Keep Reading →
September 3 - News - Comments
What should a smart Santarus, Inc. (NASDAQ:SNTS) investor do? In the financial world, there are a multitude of gauges investors can use to watch publicly...
Keep Reading →
August 30 - News - Comments
Is it smart to be bullish on Sarepta Therapeutics Inc (NASDAQ:SRPT)? If you were to ask many of your fellow readers, hedge funds are seen as overrated...
Keep Reading →
August 30 - News - Comments
Drugs fail their clinical trials for all kinds of reasons. Sometimes, it’s related to efficacy; sometimes, it’s safety related. Most of the...
Keep Reading →
August 30 - News - Comments
Are you curious what the richest investors think about VIVUS, Inc. (NASDAQ:VVUS)? In the 21st century investor’s toolkit, there are dozens of metrics...
Keep Reading →
August 22 - News - Comments
Suppose we filled a jar with slips of paper with the names of biotech companies that have been around for at least 10 years and with a market cap of at...
Keep Reading →
July 24 - News - Comments
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) investors should pay attention to an increase in activity from the world’s largest hedge funds recently...
Keep Reading →
June 21 - News - Comments
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds’ portfolio at the end of March. NKTR has experienced a decrease in support from the world...
Keep Reading →
June 12 - News - Comments
Regardless of Anchor, Things Are Looking Up! It has been a rough year for Amarin Corporation plc (ADR) (NASDAQ:AMRN) and its long-term investors. The...
Keep Reading →
June 3 - News - Comments
Santarus, Inc. (NASDAQ:SNTS) investors should pay attention to a decrease in hedge fund interest in recent months. If you’d ask most shareholders...
Keep Reading →
June 3 - News - Comments
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds’ portfolio at the end of March. SRPT shareholders have witnessed an increase in enthusiasm...
Keep Reading →
June 3 - News - Comments
Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds’ portfolio at the end of the fourth quarter of 2012. ACOR investors should pay attention...
Keep Reading →
April 12 - News - Comments
The global economy is still going through the initial stages of recovery and waiting on positive news from European markets. This bad economy has created...
Keep Reading →
March 19 - Insider Trading - Comments
